ADVERTISEMENT
  • Home
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms of Service
  • Editorial Guidelines
Thursday, July 7, 2022
Life Care News
  • Home
  • Business
    • BusinessWire
    • GlobeNewswire
    • Banking
  • News

    Chennai Firm Executes Gold Plating Work for Kerala Temple

    Pancham Dham Nyas Announces Unfurling of Sanatan Flags in 52 Countries Around Indian Ocean

    NR Group Bags the Top Exports Award for Agarbathi

    GODI, the First Indian Company to Receive BIS Certification to Sell Li-ion Cells in India with Cells made with In-house Technology for Electric Vehicles

    Gurugram Based Real Estate Development Organisation Whiteland Corporation Appoints Adil Altaf as President – Sales and CRM

    Meta Kalvi, Tamil Nadu’s First Virtual Reality Lab for Education, Launched on Metaverse for Government Schools, Chennai

    Professor Sir Ralf Speth, Chairman of TVS Motor Company, Admitted as a Fellow of The Royal Society

    IGP Launches Designer Rakhi Collection, With Over 3000+ Designs

    SBI Card Partners with Aditya Birla Finance to Launch ‘Aditya Birla SBI Card’

    TVS Motor Company Sales Grows by 22 percent in June 2022

    Trending Tags

    • Donald Trump
    • Future of News
    • Climate Change
    • Market Stories
    • Election Results
    • Flat Earth
    • Startups
    • Feature News
    • Energy
    • Real Estate
    • Environment
    • Uncategorized
  • Tech

    NORD Duodrive Now With Powers Of Up To 3 Kw Patented Geared Motor For Ultimate Energy Efficiency

    MTAR Technologies Limited Receives Orders of USD 22.12 Million in Clean Energy

    Rohde & Schwarz Offers New Ultra-Wideband Test Solution Validated for FiRa Consortium PHY Conformance

    Power League Gaming Names Langoor as New Digital Transformation Agency Partner

    Rohde & Schwarz extends the R&S ZNB vector network analyzer family maximum frequency to 43.5 GHz

    Rohde & Schwarz enhances R&S RTP high-performance oscilloscope

    Automating Battery Production for eMobility Applications

    ecom instruments at the Hannover Messe 2022: Smart Devices for the Digitalization of Hazardous Areas

    The Fischer family has created the technology group Conextivity to extend its expertise and innovation

    RAMINFO growth momentum continues in Q4 FY22 with 366% YoY rise in Net Profit

    Trending Tags

    • Flat Earth
    • Sillicon Valley
    • Mr. Robot
    • MotoGP 2017
    • Golden Globes
    • Future of News
  • Entertainment

    SCOTLAND’S NEWEST WHISKY EXPERIENCE OPENS WITH CELEBRITY CHEF TO BRING A FRESH PERSPECTIVE TO SCOTCH

    CGTN: How practice at local level enriches China’s governance

    TVOkids’ hot summer 2022 lineup celebrates learning,

    Four Indian students win 100% scholarships to study at Deakin University, Australia

    Artmarket.com: the Artprice 100© index up +36% in 2021

    The National Theatre for Children (NTC) Wraps Up 2021-22

    The Action Thriller Peninsula- Train to Busan 2 on Your Television Screens this Friday on Flix for all

    RED FM Announces ‘The Audio Film Project’ Season 2 with Vikram Bhatt

    Himindraa R Saxena – Sr. V.P. Finance – 9X Media takes additional charge of Distribution for the Network

    Tekno Point recognized in Now Tech Analyst Report, Asia Pacific for Adobe Services

    • Lifestyle

      kindlife’s ‘Kind Circle’ Aims to Bring Self-care and Planet-care Together

      PMJ Jewels Launches its 1st Showroom at Coimbatore

      Let’s End the Summer Season on a Stylish Note at Phoenix Marketcity, Pune

      ChildCare Education Institute Offers No-Cost Online Course

      Author Whynde Kuehn Previews the Upcoming Release of

      First Time in World History Hindu Religion and Buddha Religion come Together and Start a Dialogue in Cambodia

      International and Domestic manufacturers and exporters from 15 countries to showcase latest in apparel, textile and fashion industry innovations at ASW 2022

      Asian Paints has Launched their 2022 Collection in Home Decor

      California Pistachio Brings to Life

      It’s Rally Time for Houston’s Teachers

      Trending Tags

      • Golden Globes
      • Mr. Robot
      • MotoGP 2017
      • Climate Change
      • Flat Earth
    • Fashion
    • Travel
  • Health
    • Food
  • Education
    • Books
  • Technology
  • Automobile
  • Sports
    • Olympic
No Result
View All Result
Life Care News
  • Home
  • Business
    • BusinessWire
    • GlobeNewswire
    • Banking
  • News

    Chennai Firm Executes Gold Plating Work for Kerala Temple

    Pancham Dham Nyas Announces Unfurling of Sanatan Flags in 52 Countries Around Indian Ocean

    NR Group Bags the Top Exports Award for Agarbathi

    GODI, the First Indian Company to Receive BIS Certification to Sell Li-ion Cells in India with Cells made with In-house Technology for Electric Vehicles

    Gurugram Based Real Estate Development Organisation Whiteland Corporation Appoints Adil Altaf as President – Sales and CRM

    Meta Kalvi, Tamil Nadu’s First Virtual Reality Lab for Education, Launched on Metaverse for Government Schools, Chennai

    Professor Sir Ralf Speth, Chairman of TVS Motor Company, Admitted as a Fellow of The Royal Society

    IGP Launches Designer Rakhi Collection, With Over 3000+ Designs

    SBI Card Partners with Aditya Birla Finance to Launch ‘Aditya Birla SBI Card’

    TVS Motor Company Sales Grows by 22 percent in June 2022

    Trending Tags

    • Donald Trump
    • Future of News
    • Climate Change
    • Market Stories
    • Election Results
    • Flat Earth
    • Startups
    • Feature News
    • Energy
    • Real Estate
    • Environment
    • Uncategorized
  • Tech

    NORD Duodrive Now With Powers Of Up To 3 Kw Patented Geared Motor For Ultimate Energy Efficiency

    MTAR Technologies Limited Receives Orders of USD 22.12 Million in Clean Energy

    Rohde & Schwarz Offers New Ultra-Wideband Test Solution Validated for FiRa Consortium PHY Conformance

    Power League Gaming Names Langoor as New Digital Transformation Agency Partner

    Rohde & Schwarz extends the R&S ZNB vector network analyzer family maximum frequency to 43.5 GHz

    Rohde & Schwarz enhances R&S RTP high-performance oscilloscope

    Automating Battery Production for eMobility Applications

    ecom instruments at the Hannover Messe 2022: Smart Devices for the Digitalization of Hazardous Areas

    The Fischer family has created the technology group Conextivity to extend its expertise and innovation

    RAMINFO growth momentum continues in Q4 FY22 with 366% YoY rise in Net Profit

    Trending Tags

    • Flat Earth
    • Sillicon Valley
    • Mr. Robot
    • MotoGP 2017
    • Golden Globes
    • Future of News
  • Entertainment

    SCOTLAND’S NEWEST WHISKY EXPERIENCE OPENS WITH CELEBRITY CHEF TO BRING A FRESH PERSPECTIVE TO SCOTCH

    CGTN: How practice at local level enriches China’s governance

    TVOkids’ hot summer 2022 lineup celebrates learning,

    Four Indian students win 100% scholarships to study at Deakin University, Australia

    Artmarket.com: the Artprice 100© index up +36% in 2021

    The National Theatre for Children (NTC) Wraps Up 2021-22

    The Action Thriller Peninsula- Train to Busan 2 on Your Television Screens this Friday on Flix for all

    RED FM Announces ‘The Audio Film Project’ Season 2 with Vikram Bhatt

    Himindraa R Saxena – Sr. V.P. Finance – 9X Media takes additional charge of Distribution for the Network

    Tekno Point recognized in Now Tech Analyst Report, Asia Pacific for Adobe Services

    • Lifestyle

      kindlife’s ‘Kind Circle’ Aims to Bring Self-care and Planet-care Together

      PMJ Jewels Launches its 1st Showroom at Coimbatore

      Let’s End the Summer Season on a Stylish Note at Phoenix Marketcity, Pune

      ChildCare Education Institute Offers No-Cost Online Course

      Author Whynde Kuehn Previews the Upcoming Release of

      First Time in World History Hindu Religion and Buddha Religion come Together and Start a Dialogue in Cambodia

      International and Domestic manufacturers and exporters from 15 countries to showcase latest in apparel, textile and fashion industry innovations at ASW 2022

      Asian Paints has Launched their 2022 Collection in Home Decor

      California Pistachio Brings to Life

      It’s Rally Time for Houston’s Teachers

      Trending Tags

      • Golden Globes
      • Mr. Robot
      • MotoGP 2017
      • Climate Change
      • Flat Earth
    • Fashion
    • Travel
  • Health
    • Food
  • Education
    • Books
  • Technology
  • Automobile
  • Sports
    • Olympic
No Result
View All Result
Life Care News
No Result
View All Result
ADVERTISEMENT
Home Health

Kala Pharmaceuticals to Present Clinical Data for KPI-012,

by GlobeNewswire
01/05/2022
in Health
251 2
0
492
SHARES
1.4k
VIEWS
Share on FacebookShare on TwitterShare on WhatsApp
ADVERTISEMENT

— Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up —
— All Patients with Pain at Baseline Reported Zero Pain by Week 3 —
— KPI-012 was Well-Tolerated with No Significant Safety Issues Observed —
— On Track to Submit Investigational New Drug Application (IND) and Initiate Phase 2/3 Trial in 4Q 2022 —

ARLINGTON, Mass., May 01, 2022 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported clinical data from a Phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of severe ocular diseases driven by impaired healing. As previously disclosed, treatment with KPI-012 was well tolerated and resulted in significant improvements in patients with various persistent corneal epithelial defect (PCED) etiologies, with complete healing of the PCED in six of eight evaluable patients. The data will be presented on Tuesday, May 3 in a poster session at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.

“The clinical activity observed to date with KPI-012 is encouraging,” said Valeria Sánchez-Huerta, M.D. FACS, Medical Director at Asociación para Evitar la Ceguera en México (Association to Prevent Blindness in Mexico) and an investigator in the Phase 1b trial. “PCED is a disease of impaired corneal healing which, if left untreated, can lead to infection, corneal perforation and irreversible vision loss. Achieving rapid and complete wound healing, as well as a reduction in PCED-related pain, and an improvement in visual acuity and corneal opacity, in patients with a range of underlying etiologies is remarkable, particularly after such a short treatment duration. Based on these early data, I believe KPI-012 could become the first treatment to address PCED across all etiologies and I look forward to further evaluating its potential in later-stage studies.”

ADVERTISEMENT

PCED, which is defined as a persistent non-healing corneal defect or wound that is refractory to conventional treatments, is a rare disease with an estimated incidence in the United States of 100,000 cases per year. PCED can have various etiologies, including neurotrophic keratitis, surgical epithelial debridement, microbial/viral keratitis, corneal transplant, limbal stem cell deficiency and mechanical and chemical trauma and can lead to corneal ulceration, perforation, stromal scarring, secondary infections and significant vision loss.

Healing after corneal injury follows a highly coordinated process involving growth factors, cell signaling, proliferation, migration and extracellular matrix remodeling. In patients with PCED, there is an imbalance of key biomolecules, including growth factors and cytokines, which results in significant inflammation, impaired innervation and disruption of the protective corneal epithelial and stromal layers. KPI-012 was designed specifically to address this imbalance: it is a novel, human bone marrow-derived mesenchymal stem cell (MSC) secretome containing numerous human biomolecules, including protease inhibitors, matrix proteins, growth factors and neurotrophic factors, that provide a multifactorial mechanism of action to address impaired corneal healing across numerous etiologies.

“We are pleased to present these exciting data from the first KPI-012 clinical trial,” said Kim Brazzell, Ph.D., Head of Research and Development and Chief Medical Officer at Kala Pharmaceuticals. “These data, which served as the foundation for our acquisition of Combangio last year, highlight the potential of KPI-012 to deliver a novel approach to treating PCED, as well as other rare front and back of the eye diseases. Our goal remains to advance KPI-012 into a Phase 2/3 trial for PCED later this year, as we aim to deliver new and better options to people living with severe ocular surface diseases.”

The poster presentation is now available on the Kala Pharmaceuticals website at https://investors.kalarx.com/presentations.

Highlights from the ARVO Presentation

Advertisement. Scroll to continue reading.
Advertisement. Scroll to continue reading.

The single-arm, prospective, open-label Phase 1b clinical trial enrolled 12 patients, including three who were enrolled in a safety lead-in cohort and nine enrolled in an efficacy cohort. Within the efficacy cohort, patients presented with PCED of various etiologies and durations ranging from 15 to 871 days. Patients were treated with twice daily KPI-012 for up to four weeks, with follow-up occurring at two, four and 12 weeks after their last dose of therapy. The key efficacy endpoint was complete healing of the corneal defects evaluated by corneal staining. Other efficacy endpoints included reduction in defect size, visual acuity, and corneal opacity. Safety measures included tolerability/pain, intraocular pressure and adverse events.

Eight patients were evaluable for efficacy assessment; one participant was ineligible due to a non-treatment related adverse event. Improvement was seen in seven of the eight evaluable patients, with six of the eight achieving complete healing by the end of Week 4, including four patients who were healed by the end of Week 1 and one patient who was healed by the end of Week 2. All six healed patients remained healed through the end of the follow-up period. In addition, improvement in PCED lesion size was observed in both patients who did not experience full wound healing. Across all eight patients, the mean improvement in lesion size from baseline to end of treatment was -16.23 mm. KPI-012 was well-tolerated in the trial.

Clinical Development Plans

Kala plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) and, subject to regulatory clearance, initiate a Phase 2/3 clinical trial of KPI-012 in PCED patients in the fourth quarter of 2022. Kala believes this trial could serve as the first of two required pivotal trials. The FDA has granted KPI-012 Orphan Designation for the treatment of PCED and the Company believes it could also meet the criteria for fast-track and breakthrough designations.

In addition, Kala believes the multifactorial mechanism of action of KPI-012 also makes it a platform technology and is evaluating KPI-012 for potential expansion to indications for rare front of the eye diseases, such as limbal stem cell deficiency and Sjogren’s Syndrome, as well as select rare back of the eye diseases, such as retinitis pigmentosa and optic neuritis.

About Kala Pharmaceuticals, Inc.

Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%. The Company also has a pipeline of development programs including a clinical-stage secretome product candidate, KPI-012, initially targeting persistent corneal epithelial defects (PCED) and multiple proprietary new chemical entity (NCE) preclinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. Any statements in this press release about Kala’s future expectations, plans and prospects, including but not limited to statements about Kala’s expectations with respect to KPI-012, the future development or commercialization of KPI-012, conduct and timelines of clinical trials, Kala’s plans to progress its pipeline of preclinical development programs targeted to address front and back of the eye diseases, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those discussed in the “Risk Factors” section of Kala’s Annual Report on Form 10-K, most recently filed Quarterly Report on Form 10-Q and other filings Kala makes with the Securities and Exchange Commission. These forward-looking statements represent the Company’s views as of the date of this release and should not be relied upon as representing the Kala’s views as of any date subsequent to the date hereof. Kala does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Advertisement. Scroll to continue reading.
ADVERTISEMENT

Investor Contacts:

Jill Steier
jill.steier@kalarx.com
781-996-5252

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

ADVERTISEMENT

 

Tags: clinicaldataIncKalaKala PharmaceuticalsKPI012Nasdaq:KALAPharmaceuticalsPresent
Share197Tweet123Send
ADVERTISEMENT
Previous Post

$RISE Token Launches On TrustSwap Launchpad On May 10th,

Next Post

FIBROGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of FibroGen, Inc. – FGEN

GlobeNewswire

GlobeNewswire

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Next Post

FIBROGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of FibroGen, Inc. - FGEN

  • Trending
  • Comments
  • Latest

GreenCell Mobility Unveils ‘NueGo’ – First Pan-India Intercity Electric Mobility Coach Brand

22/04/2022

Sinch AB (publ) has published its Annual Report for 2021

22/04/2022

HarperCollins Presents THE RESILIENT SOCIETY: Economics After Covid by Markus Brunnermeier

22/04/2022

Mind Wars To Organise Mumbai Debate Championship 2021 : Zee Entertainment

ABP Network celebrated Doctors Day with special programming initiatives

Coca-Cola India appointment Devyani Rajya Laxmi Rana as Vice President of Public Affairs for India and Southwest Asia

Coca-Cola India appointment Devyani Rajya Laxmi Rana as Vice President of Public Affairs for India and Southwest Asia

Yakult Danone India Pvt. Ltd. and SRM University, Delhi-NCR, Sonepat, Haryana Sign Memorandum of Understanding (MoU)

07/07/2022

Abracon Announces Acquisition by Genstar Capital; Tony Roybal Named President and CEO, Michael Calabria Executive Chairman

07/07/2022

SCOTLAND’S NEWEST WHISKY EXPERIENCE OPENS WITH CELEBRITY CHEF TO BRING A FRESH PERSPECTIVE TO SCOTCH

07/07/2022
ADVERTISEMENT
ADVERTISEMENT
Life Care News

Copyright © 2015 - 2021 Lifecarenews.in

LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283

  • Home
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms of Service
  • Editorial Guidelines

Follow Us

No Result
View All Result
  • Home
  • Business
    • BusinessWire
    • GlobeNewswire
    • Banking
  • News
    • Startups
    • Feature News
    • Energy
    • Real Estate
    • Environment
    • Uncategorized
  • Tech
  • Entertainment
    • Lifestyle
    • Fashion
    • Travel
  • Health
    • Food
  • Education
    • Books
  • Technology
  • Automobile
  • Sports
    • Olympic

Copyright © 2015 - 2021 Lifecarenews.in

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Go to mobile version